| Patents for C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof (291,526) |
|---|
| 03/03/2011 | CA2772204A1 Methods and compositions for the inhibition of transplant rejection |
| 03/03/2011 | CA2772199A1 B7-h4 fusion proteins and methods of use thereof |
| 03/03/2011 | CA2772162A1 Il-17 binding compounds and medical uses thereof |
| 03/03/2011 | CA2772106A1 Fusarium and fusarium mycotoxin biocontrol |
| 03/03/2011 | CA2772104A1 Hybrid polypeptides including meningococcal fhbp sequences |
| 03/03/2011 | CA2771927A1 Proteins relating to grain shape and leaf shape of rice, coding genes and uses thereof |
| 03/03/2011 | CA2771781A1 Antikine antibodies that bind to multiple cc chemokines |
| 03/03/2011 | CA2771769A1 Urocortin 2 analogs and uses thereof |
| 03/03/2011 | CA2771328A1 Cofactors for thrombin activation of factor vii and uses thereof |
| 03/03/2011 | CA2754024A1 Antibody fusion-mediated plant resistance against oomycota |
| 03/02/2011 | EP2290109A2 Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses |
| 03/02/2011 | EP2290108A2 Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses |
| 03/02/2011 | EP2290105A1 Method for detecting cellular proliferative disorders |
| 03/02/2011 | EP2290104A2 Identification of surface-associated Antigenes used for the diagnosis and therapy of tumours |
| 03/02/2011 | EP2290103A2 Identification of surface-associated Antigenes used for the diagnosis and therapy of tumours |
| 03/02/2011 | EP2290091A2 Recombinant measles viruses expressing epitopes of antigens of RNA viruses and use of the recombinant viruses for the preparation of vaccine compositions |
| 03/02/2011 | EP2290088A1 Methods for producing soluble multi-menbrane-spanning proteins |
| 03/02/2011 | EP2290087A2 Methods for producing soluble multi-membrane-spanning proteins |
| 03/02/2011 | EP2290086A2 Methods for producing soluble multi-membrane-spanning proteins |
| 03/02/2011 | EP2290083A1 Conserved neisserial antigens |
| 03/02/2011 | EP2290082A1 Streptococcus pyogenes antigens |
| 03/02/2011 | EP2290081A2 IL-17 homologous polypeptide and therapeutic uses thereof |
| 03/02/2011 | EP2290080A2 Compositions and methods for diagnosing or treating psoriasis |
| 03/02/2011 | EP2290079A2 Neurotrophic factors |
| 03/02/2011 | EP2290077A2 Natural IGM antibodies and inhibitors thereof |
| 03/02/2011 | EP2290062A1 Corynebacterium glutamicum gene encoding phosphoenolpyruvate carboxykinase |
| 03/02/2011 | EP2290053A1 Method for producing Influenza virus in protein-free cell culture medium |
| 03/02/2011 | EP2289938A2 Use of Panton-Valentine Leukocidin for treating and preventing staphylococcus infections |
| 03/02/2011 | EP2289935A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289934A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289933A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289932A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289931A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289930A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289929A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289928A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289927A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289926A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289925A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289924A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289923A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289922A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289921A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289920A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289919A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289918A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289917A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289916A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289915A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289914A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289913A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289912A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289911A2 Therapeutic use of a growth factor, NsG33 |
| 03/02/2011 | EP2289910A2 Differential in tumour gene products and use of same |
| 03/02/2011 | EP2289909A1 Screening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodies |
| 03/02/2011 | EP2289908A1 Use of DG177 secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome |
| 03/02/2011 | EP2289907A2 Streptococcus agalactiae antigens I + II |
| 03/02/2011 | EP2289906A1 Borrelia antigens |
| 03/02/2011 | EP2289567A2 Matrix comprising naturally-occurring crosslinked protein backbone |
| 03/02/2011 | EP2289551A1 Immunotherapy of autoimmune disorders using antibodies which target B-cells |
| 03/02/2011 | EP2289547A1 Vaccine for treatment and prevention of herpes simplex virus infection |
| 03/02/2011 | EP2289546A2 Injectable vaccines against multiple meningococcal serogroups |
| 03/02/2011 | EP2289544A2 Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto |
| 03/02/2011 | EP2289542A1 Treatment of neurological or neurodegenerative disorders |
| 03/02/2011 | EP2289541A1 Treatment of neurological or neurodegenerative disorders |
| 03/02/2011 | EP2289536A1 Use of bone morphogenetic proteins for healing and repair of connective tissue attachment |
| 03/02/2011 | EP2289535A2 Compositions and methods for promoting wound healing and tissue regeneration |
| 03/02/2011 | EP2289533A1 Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides |
| 03/02/2011 | EP2289532A1 Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides |
| 03/02/2011 | EP2289531A2 Medicaments for increasing endogenous erythropoietine (EPO) |
| 03/02/2011 | EP2289525A1 Use of IL-21 for expanding lymphoid cells and for anticancer adoptive immunotherapy |
| 03/02/2011 | EP2289516A1 Methods and means for the treatment of HPV induced intraepithelial neoplasias |
| 03/02/2011 | EP2288708A1 Armyworm insect resistance management in transgenic plants |
| 03/02/2011 | EP2288702A1 Combination therapies against cancer |
| 03/02/2011 | EP2288700A1 Hbv epitope reactive exogenous t cell receptor (tcr) and uses thereof |
| 03/02/2011 | EP2288693A1 Novel astrovirus |
| 03/02/2011 | EP2288624A2 Compositions and methods for inhibiting shiga toxin and shiga-like toxin |
| 03/02/2011 | EP2288622A2 Modified factor ix polypeptides and uses thereof |
| 03/02/2011 | EP2288621A2 Il-23 receptor antagonists and uses thereof |
| 03/02/2011 | EP2288620A2 Hybrid proteins comprising membrane receptor and ion channel, and their use as biosensors |
| 03/02/2011 | EP2288619A2 Cyclized non-native synthetic peptide and complex of peptides comprising said cyclized peptide, intended to induce and to characterize the prevention or treatment of conditions in mammals |
| 03/02/2011 | EP2288618A1 Chimeric fusion proteins and virus like particles from birnavirus vp2 |
| 03/02/2011 | EP2288617A1 Polypeptide |
| 03/02/2011 | EP2288616A1 Peptidylarginine deiminase (pad) inhibitors |
| 03/02/2011 | EP2288615A1 Selective caspase inhibitors and uses thereof |
| 03/02/2011 | EP2288386A1 Modified linkers |
| 03/02/2011 | EP2288374A2 Novel n-and c-terminal substituted antagonistic analogs of human gh-rh |
| 03/02/2011 | EP2288373A2 Treating dyspnea associated with acute heart failure with relaxin |
| 03/02/2011 | EP2288366A2 Method of treating chronic heart failure |
| 03/02/2011 | EP2288359A1 Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents |
| 03/02/2011 | EP2010563B1 Synthetic mecp2 sequence for protein substitution therapy |
| 03/02/2011 | EP1984736B1 Cd86 and cd80 receptor competition assays |
| 03/02/2011 | EP1954710B1 Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides |
| 03/02/2011 | EP1844070B1 Peptides with neuropeptide-2 receptor (y2r) agonist activity |
| 03/02/2011 | EP1740699B1 Connexin 40 tissue specific gene mutations |
| 03/02/2011 | EP1673633B9 Method for detecting feline immunodeficiency virus |
| 03/02/2011 | EP1668030B1 A method of improving efficacy of biological response-modifying proteins and the exemplary muteins |
| 03/02/2011 | EP1650225B1 Hetero type pentamer recombinant vaccine |
| 03/02/2011 | EP1639004B1 Fluorescein-labelled peptides |
| 03/02/2011 | EP1625159B1 Materials and methods relating to g-protein coupled receptor oligomers |